Home > > Asia And Global Vaccines Market- Size, Share, Growth Rate, and Forecast
TABLE OF CONTENTS CHAPTER 1: RESEARCH METHODOLOGY 1.1. Delivery Model 1.2. Hypothesis Creation 1.3. Revenue narrow down of Companies and in-depth interviews 1.4. Data Triangulation and Validation 1.5. About Us 1.6. Key market segments CHAPTER 2: PREMIUM INSIGHTS CHAPTER 3: ASIA VACCINES MARKET 3.1. OVERVIEW 3.2. ASIA 3.2.1. ASIA VACCINES MARKET, BY TECHNOLOGY 3.2.2. ASIA VACCINES MARKET, BY TYPE 3.2.3. ASIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION 3.2.4. ASIA VACCINES MARKET, BY COUNTRY 3.2.4.1. JAPAN 3.2.4.1.1. JAPAN VACCINES MARKET, BY TECHNOLOGY 3.2.4.1.2. JAPAN VACCINES MARKET, BY TYPE 3.2.4.1.3. JAPAN VACCINES MARKET, BY ROUTE OF ADMINISTRATION 3.2.4.2. CHINA 3.2.4.2.1. CHINA VACCINES MARKET, BY TECHNOLOGY 3.2.4.2.2. CHINA VACCINES MARKET, BY TYPE 3.2.4.2.3. CHINA VACCINES MARKET, BY ROUTE OF ADMINISTRATION 3.2.4.3. INDIA 3.2.4.3.1. INDIA VACCINES MARKET, BY TECHNOLOGY 3.2.4.3.2. INDIA VACCINES MARKET, BY TYPE 3.2.4.3.3. INDIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION 3.2.4.4. ROAPAC 3.2.4.4.1. ROAPAC VACCINES MARKET, BY TECHNOLOGY 3.2.4.4.2. ROAPAC VACCINES MARKET, BY TYPE 3.2.4.4.3. ROAPAC VACCINES MARKET, BY ROUTE OF ADMINISTRATION CHAPTER 4: GLOBAL VACCINES MARKET, BY TECHNOLOGY 4.1. OVERVIEW 4.2. CONJUGATE VACCINES 4.2.1. CONJUGATE VACCINES MARKET, BY REGION 4.2.1.1. NORTH AMERICA CONJUGATE VACCINES MARKET, BY COUNTRY 4.2.1.2. EUROPE CONJUGATE VACCINES MARKET, BY COUNTRY 4.2.1.3. ASIA CONJUGATE VACCINES MARKET, BY COUNTRY 4.2.1.4. MIDDLE EAST & AFRICA CONJUGATE VACCINES MARKET, BY COUNTRY 4.3. INACTIVATED AND SUBUNIT VACCINES 4.3.1. INACTIVATED AND SUBUNIT VACCINES MARKET, BY REGION 4.3.1.1. NORTH AMERICA INACTIVATED AND SUBUNIT VACCINES MARKET, BY COUNTRY 4.3.1.2. EUROPE INACTIVATED AND SUBUNIT VACCINES MARKET, BY COUNTRY 4.3.1.3. ASIA INACTIVATED AND SUBUNIT VACCINES MARKET, BY COUNTRY 4.3.1.4. MIDDLE EAST & AFRICA INACTIVATED AND SUBUNIT VACCINES MARKET, BY COUNTRY 4.4. LIVE ATTENUATED VACCINES 4.4.1. LIVE ATTENUATED VACCINES MARKET, BY REGION 4.4.1.1. NORTH AMERICA LIVE ATTENUATED VACCINES MARKET, BY COUNTRY 4.4.1.2. EUROPE LIVE ATTENUATED VACCINES MARKET, BY COUNTRY 4.4.1.3. ASIA LIVE ATTENUATED VACCINES MARKET, BY COUNTRY 4.4.1.4. MIDDLE EAST & AFRICA LIVE ATTENUATED VACCINES MARKET, BY COUNTRY 4.5. RECOMBINANT VACCINES 4.5.1. RECOMBINANT VACCINES MARKET, BY REGION 4.5.1.1. NORTH AMERICA RECOMBINANT VACCINES MARKET, BY COUNTRY 4.5.1.2. EUROPE RECOMBINANT VACCINES MARKET, BY COUNTRY 4.5.1.3. ASIA RECOMBINANT VACCINES MARKET, BY COUNTRY 4.5.1.4. MIDDLE EAST & AFRICA RECOMBINANT VACCINES MARKET, BY COUNTRY 4.6. TOXOID VACCINES 4.6.1. TOXOID VACCINES MARKET, BY REGION 4.6.1.1. NORTH AMERICA TOXOID VACCINES MARKET, BY COUNTRY 4.6.1.2. EUROPE TOXOID VACCINES MARKET, BY COUNTRY 4.6.1.3. ASIA TOXOID VACCINES MARKET, BY COUNTRY 4.6.1.4. MIDDLE EAST & AFRICA TOXOID VACCINES MARKET, BY COUNTRY CHAPTER 5: GLOBAL VACCINES MARKET, BY TYPE 5.1. OVERVIEW 5.2. MONOVALENT VACCINES 5.2.1. MONOVALENT VACCINES MARKET, BY REGION 5.2.1.1. NORTH AMERICA MONOVALENT VACCINES MARKET, BY COUNTRY 5.2.1.2. EUROPE MONOVALENT VACCINES MARKET, BY COUNTRY 5.2.1.3. ASIA MONOVALENT VACCINES MARKET, BY COUNTRY 5.2.1.4. MIDDLE EAST & AFRICA MONOVALENT VACCINES MARKET, BY COUNTRY 5.3. MULTIVALENT VACCINES 5.3.1. MULTIVALENT VACCINES MARKET, BY REGION 5.3.1.1. NORTH AMERICA MULTIVALENT VACCINES MARKET, BY COUNTRY 5.3.1.2. EUROPE MULTIVALENT VACCINES MARKET, BY COUNTRY 5.3.1.3. ASIA MULTIVALENT VACCINES MARKET, BY COUNTRY 5.3.1.4. MIDDLE EAST & AFRICA MULTIVALENT VACCINES MARKET, BY COUNTRY CHAPTER 6: GLOBAL VACCINES MARKET, BY ROUTE OF ADMINISTRATION 6.1. OVERVIEW 6.2. INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION 6.2.1. INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET, BY REGION 6.2.1.1. NORTH AMERICA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET, BY COUNTRY 6.2.1.2. EUROPE INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET, BY COUNTRY 6.2.1.3. ASIA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET, BY COUNTRY 6.2.1.4. MIDDLE EAST & AFRICA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET, BY COUNTRY 6.3. ORAL ADMINISTRATION 6.3.1. ORAL ADMINISTRATION MARKET, BY REGION 6.3.1.1. NORTH AMERICA ORAL ADMINISTRATION MARKET, BY COUNTRY 6.3.1.2. EUROPE ORAL ADMINISTRATION MARKET, BY COUNTRY 6.3.1.3. ASIA ORAL ADMINISTRATION MARKET, BY COUNTRY 6.3.1.4. MIDDLE EAST & AFRICA ORAL ADMINISTRATION MARKET, BY COUNTRY 6.4. OTHER ROUTES OF ADMINISTRATION 6.4.1. OTHER ROUTES OF ADMINISTRATION MARKET, BY REGION 6.4.1.1. NORTH AMERICA OTHER ROUTES OF ADMINISTRATION MARKET, BY COUNTRY 6.4.1.2. EUROPE OTHER ROUTES OF ADMINISTRATION MARKET, BY COUNTRY 6.4.1.3. ASIA OTHER ROUTES OF ADMINISTRATION MARKET, BY COUNTRY 6.4.1.4. MIDDLE EAST & AFRICA OTHER ROUTES OF ADMINISTRATION MARKET, BY COUNTRY TABLE 75. MIDDLE EAST & AFRICA OTHER ROUTES OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION)LIST OF TABLES TABLE 01. GLOBAL VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 02. GLOBAL VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 03. TABLE 04. SOURCE: PRIMARY RESEARCH, GOVERNMENT PUBLICATIONS, COMPANY RELEASES, AND 1000IQMR ANALYSISGLOBAL VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 05. GLOBAL VACCINES MARKET VALUE, BY REGION, 2023-2030, ($MILLION) TABLE 06. GLOBAL VACCINES MARKET VALUE, BY REGION, 2023-2030, ($MILLION) TABLE 07. ASIA VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($MILLION) TABLE 08. ASIA VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($MILLION) TABLE 09. ASIA VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($MILLION) TABLE 10. ASIA VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 11. JAPAN VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 12. JAPAN VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 13. JAPAN VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 14. CHINA VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 15. CHINA VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 16. CHINA VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 17. INDIA VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 18. INDIA VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 19. INDIA VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 20. ROAPAC VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 21. ROAPAC VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 22. ROAPAC VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 23. GLOBAL VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 24. CONJUGATE VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 25. NORTH AMERICA CONJUGATE VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 26. EUROPE CONJUGATE VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 27. ASIA CONJUGATE VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 28. MIDDLE EAST & AFRICA CONJUGATE VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 29. INACTIVATED AND SUBUNIT VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 30. NORTH AMERICA INACTIVATED AND SUBUNIT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 31. EUROPE INACTIVATED AND SUBUNIT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 32. ASIA INACTIVATED AND SUBUNIT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 33. MIDDLE EAST & AFRICA INACTIVATED AND SUBUNIT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 34. LIVE ATTENUATED VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 35. NORTH AMERICA LIVE ATTENUATED VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 36. EUROPE LIVE ATTENUATED VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 37. ASIA LIVE ATTENUATED VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 38. MIDDLE EAST & AFRICA LIVE ATTENUATED VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 39. RECOMBINANT VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 40. NORTH AMERICA RECOMBINANT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 41. EUROPE RECOMBINANT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 42. ASIA RECOMBINANT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 43. MIDDLE EAST & AFRICA RECOMBINANT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 44. TOXOID VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 45. NORTH AMERICA TOXOID VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 46. EUROPE TOXOID VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 47. ASIA TOXOID VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 48. MIDDLE EAST & AFRICA TOXOID VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 49. GLOBAL VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 50. MONOVALENT VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 51. NORTH AMERICA MONOVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 52. EUROPE MONOVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 53. ASIA MONOVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 54. MIDDLE EAST & AFRICA MONOVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 55. MULTIVALENT VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 56. NORTH AMERICA MULTIVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 57. EUROPE MULTIVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 58. ASIA MULTIVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 59. MIDDLE EAST & AFRICA MULTIVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 60. GLOBAL VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 61. INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 62. NORTH AMERICA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 63. EUROPE INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 64. ASIA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 65. MIDDLE EAST & AFRICA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 66. ORAL ADMINISTRATION MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 67. NORTH AMERICA ORAL ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 68. EUROPE ORAL ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 69. ASIA ORAL ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 70. MIDDLE EAST & AFRICA ORAL ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 71. OTHER ROUTES OF ADMINISTRATION MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 72. NORTH AMERICA OTHER ROUTES OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 73. EUROPE OTHER ROUTES OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 74. ASIA OTHER ROUTES OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 75. MIDDLE EAST & AFRICA OTHER ROUTES OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION)LIST OF FIGURES CHAPTER 1: RESEARCH METHODOLOGY 1.1. Delivery Model 1.2. Hypothesis Creation 1.3. Revenue narrow down of Companies and in-depth interviews 1.4. Data Triangulation and Validation 1.5. About Us 1.6. Key market segments CHAPTER 2: PREMIUM INSIGHTS CHAPTER 3: ASIA VACCINES MARKET 3.1. OVERVIEW 3.2. ASIA 3.2.1. ASIA VACCINES MARKET, BY TECHNOLOGY 3.2.2. ASIA VACCINES MARKET, BY TYPE 3.2.3. ASIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION 3.2.4. ASIA VACCINES MARKET, BY COUNTRY 3.2.4.1. JAPAN 3.2.4.1.1. JAPAN VACCINES MARKET, BY TECHNOLOGY 3.2.4.1.2. JAPAN VACCINES MARKET, BY TYPE 3.2.4.1.3. JAPAN VACCINES MARKET, BY ROUTE OF ADMINISTRATION 3.2.4.2. CHINA 3.2.4.2.1. CHINA VACCINES MARKET, BY TECHNOLOGY 3.2.4.2.2. CHINA VACCINES MARKET, BY TYPE 3.2.4.2.3. CHINA VACCINES MARKET, BY ROUTE OF ADMINISTRATION 3.2.4.3. INDIA 3.2.4.3.1. INDIA VACCINES MARKET, BY TECHNOLOGY 3.2.4.3.2. INDIA VACCINES MARKET, BY TYPE 3.2.4.3.3. INDIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION 3.2.4.4. ROAPAC 3.2.4.4.1. ROAPAC VACCINES MARKET, BY TECHNOLOGY 3.2.4.4.2. ROAPAC VACCINES MARKET, BY TYPE 3.2.4.4.3. ROAPAC VACCINES MARKET, BY ROUTE OF ADMINISTRATION CHAPTER 4: GLOBAL VACCINES MARKET, BY TECHNOLOGY 4.1. OVERVIEW 4.2. CONJUGATE VACCINES 4.2.1. CONJUGATE VACCINES MARKET, BY REGION 4.2.1.1. NORTH AMERICA CONJUGATE VACCINES MARKET, BY COUNTRY 4.2.1.2. EUROPE CONJUGATE VACCINES MARKET, BY COUNTRY 4.2.1.3. ASIA CONJUGATE VACCINES MARKET, BY COUNTRY 4.2.1.4. MIDDLE EAST & AFRICA CONJUGATE VACCINES MARKET, BY COUNTRY 4.3. INACTIVATED AND SUBUNIT VACCINES 4.3.1. INACTIVATED AND SUBUNIT VACCINES MARKET, BY REGION 4.3.1.1. NORTH AMERICA INACTIVATED AND SUBUNIT VACCINES MARKET, BY COUNTRY 4.3.1.2. EUROPE INACTIVATED AND SUBUNIT VACCINES MARKET, BY COUNTRY 4.3.1.3. ASIA INACTIVATED AND SUBUNIT VACCINES MARKET, BY COUNTRY 4.3.1.4. MIDDLE EAST & AFRICA INACTIVATED AND SUBUNIT VACCINES MARKET, BY COUNTRY 4.4. LIVE ATTENUATED VACCINES 4.4.1. LIVE ATTENUATED VACCINES MARKET, BY REGION 4.4.1.1. NORTH AMERICA LIVE ATTENUATED VACCINES MARKET, BY COUNTRY 4.4.1.2. EUROPE LIVE ATTENUATED VACCINES MARKET, BY COUNTRY 4.4.1.3. ASIA LIVE ATTENUATED VACCINES MARKET, BY COUNTRY 4.4.1.4. MIDDLE EAST & AFRICA LIVE ATTENUATED VACCINES MARKET, BY COUNTRY 4.5. RECOMBINANT VACCINES 4.5.1. RECOMBINANT VACCINES MARKET, BY REGION 4.5.1.1. NORTH AMERICA RECOMBINANT VACCINES MARKET, BY COUNTRY 4.5.1.2. EUROPE RECOMBINANT VACCINES MARKET, BY COUNTRY 4.5.1.3. ASIA RECOMBINANT VACCINES MARKET, BY COUNTRY 4.5.1.4. MIDDLE EAST & AFRICA RECOMBINANT VACCINES MARKET, BY COUNTRY 4.6. TOXOID VACCINES 4.6.1. TOXOID VACCINES MARKET, BY REGION 4.6.1.1. NORTH AMERICA TOXOID VACCINES MARKET, BY COUNTRY 4.6.1.2. EUROPE TOXOID VACCINES MARKET, BY COUNTRY 4.6.1.3. ASIA TOXOID VACCINES MARKET, BY COUNTRY 4.6.1.4. MIDDLE EAST & AFRICA TOXOID VACCINES MARKET, BY COUNTRY CHAPTER 5: GLOBAL VACCINES MARKET, BY TYPE 5.1. OVERVIEW 5.2. MONOVALENT VACCINES 5.2.1. MONOVALENT VACCINES MARKET, BY REGION 5.2.1.1. NORTH AMERICA MONOVALENT VACCINES MARKET, BY COUNTRY 5.2.1.2. EUROPE MONOVALENT VACCINES MARKET, BY COUNTRY 5.2.1.3. ASIA MONOVALENT VACCINES MARKET, BY COUNTRY 5.2.1.4. MIDDLE EAST & AFRICA MONOVALENT VACCINES MARKET, BY COUNTRY 5.3. MULTIVALENT VACCINES 5.3.1. MULTIVALENT VACCINES MARKET, BY REGION 5.3.1.1. NORTH AMERICA MULTIVALENT VACCINES MARKET, BY COUNTRY 5.3.1.2. EUROPE MULTIVALENT VACCINES MARKET, BY COUNTRY 5.3.1.3. ASIA MULTIVALENT VACCINES MARKET, BY COUNTRY 5.3.1.4. MIDDLE EAST & AFRICA MULTIVALENT VACCINES MARKET, BY COUNTRY CHAPTER 6: GLOBAL VACCINES MARKET, BY ROUTE OF ADMINISTRATION 6.1. OVERVIEW 6.2. INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION 6.2.1. INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET, BY REGION 6.2.1.1. NORTH AMERICA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET, BY COUNTRY 6.2.1.2. EUROPE INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET, BY COUNTRY 6.2.1.3. ASIA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET, BY COUNTRY 6.2.1.4. MIDDLE EAST & AFRICA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET, BY COUNTRY 6.3. ORAL ADMINISTRATION 6.3.1. ORAL ADMINISTRATION MARKET, BY REGION 6.3.1.1. NORTH AMERICA ORAL ADMINISTRATION MARKET, BY COUNTRY 6.3.1.2. EUROPE ORAL ADMINISTRATION MARKET, BY COUNTRY 6.3.1.3. ASIA ORAL ADMINISTRATION MARKET, BY COUNTRY 6.3.1.4. MIDDLE EAST & AFRICA ORAL ADMINISTRATION MARKET, BY COUNTRY 6.4. OTHER ROUTES OF ADMINISTRATION 6.4.1. OTHER ROUTES OF ADMINISTRATION MARKET, BY REGION 6.4.1.1. NORTH AMERICA OTHER ROUTES OF ADMINISTRATION MARKET, BY COUNTRY 6.4.1.2. EUROPE OTHER ROUTES OF ADMINISTRATION MARKET, BY COUNTRY 6.4.1.3. ASIA OTHER ROUTES OF ADMINISTRATION MARKET, BY COUNTRY 6.4.1.4. MIDDLE EAST & AFRICA OTHER ROUTES OF ADMINISTRATION MARKET, BY COUNTRY TABLE 01. GLOBAL VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 02. GLOBAL VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 03. TABLE 04. SOURCE: PRIMARY RESEARCH, GOVERNMENT PUBLICATIONS, COMPANY RELEASES, AND 1000IQMR ANALYSISGLOBAL VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 05. GLOBAL VACCINES MARKET VALUE, BY REGION, 2023-2030, ($MILLION) TABLE 06. GLOBAL VACCINES MARKET VALUE, BY REGION, 2023-2030, ($MILLION) TABLE 07. ASIA VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($MILLION) TABLE 08. ASIA VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($MILLION) TABLE 09. ASIA VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($MILLION) TABLE 10. ASIA VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 11. JAPAN VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 12. JAPAN VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 13. JAPAN VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 14. CHINA VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 15. CHINA VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 16. CHINA VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 17. INDIA VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 18. INDIA VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 19. INDIA VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 20. ROAPAC VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 21. ROAPAC VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 22. ROAPAC VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 23. GLOBAL VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 24. CONJUGATE VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 25. NORTH AMERICA CONJUGATE VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 26. EUROPE CONJUGATE VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 27. ASIA CONJUGATE VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 28. MIDDLE EAST & AFRICA CONJUGATE VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 29. INACTIVATED AND SUBUNIT VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 30. NORTH AMERICA INACTIVATED AND SUBUNIT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 31. EUROPE INACTIVATED AND SUBUNIT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 32. ASIA INACTIVATED AND SUBUNIT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 33. MIDDLE EAST & AFRICA INACTIVATED AND SUBUNIT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 34. LIVE ATTENUATED VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 35. NORTH AMERICA LIVE ATTENUATED VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 36. EUROPE LIVE ATTENUATED VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 37. ASIA LIVE ATTENUATED VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 38. MIDDLE EAST & AFRICA LIVE ATTENUATED VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 39. RECOMBINANT VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 40. NORTH AMERICA RECOMBINANT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 41. EUROPE RECOMBINANT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 42. ASIA RECOMBINANT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 43. MIDDLE EAST & AFRICA RECOMBINANT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 44. TOXOID VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 45. NORTH AMERICA TOXOID VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 46. EUROPE TOXOID VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 47. ASIA TOXOID VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 48. MIDDLE EAST & AFRICA TOXOID VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 49. GLOBAL VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 50. MONOVALENT VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 51. NORTH AMERICA MONOVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 52. EUROPE MONOVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 53. ASIA MONOVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 54. MIDDLE EAST & AFRICA MONOVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 55. MULTIVALENT VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 56. NORTH AMERICA MULTIVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 57. EUROPE MULTIVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 58. ASIA MULTIVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 59. MIDDLE EAST & AFRICA MULTIVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 60. GLOBAL VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 61. INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 62. NORTH AMERICA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 63. EUROPE INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 64. ASIA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 65. MIDDLE EAST & AFRICA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 66. ORAL ADMINISTRATION MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 67. NORTH AMERICA ORAL ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 68. EUROPE ORAL ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 69. ASIA ORAL ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 70. MIDDLE EAST & AFRICA ORAL ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 71. OTHER ROUTES OF ADMINISTRATION MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 72. NORTH AMERICA OTHER ROUTES OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 73. EUROPE OTHER ROUTES OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 74. ASIA OTHER ROUTES OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 75. MIDDLE EAST & AFRICA OTHER ROUTES OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION)